Semaglutide Compounding Ban 2026: What's Still Legal

Compounded semaglutide is no longer broadly legal in 2026. After the FDA declared the semaglutide shortage resolved in February 2025, enforcement-discretion windows for compounders closed in spring 2025. Mass-scale 503A and 503B compounding is now off-limits; narrow patient-specific 503A compounding remains permitted only under documented clinical-difference exceptions.

Semaglutide compounding at a glance

• Drug: semaglutide, a GLP-1 receptor agonist (brand names Ozempic, Wegovy, Rybelsus)
• FDA-approved products available: yes — the shortage is over
• Shortage status: declared resolved February 21, 2025
• 503A enforcement discretion: ended April 22, 2025
• 503B enforcement discretion: ended May 22, 2025
• 503B bulks list: FDA proposed to exclude semaglutide (notice published May 1, 2026; comment period through June 30, 2026)
• Still legal: patient-specific 503A compounding only under a documented clinical-difference exception (e.g., a dose or formulation not commercially available)
• Not legal: routine "essentially a copy" compounding of mass-market semaglutide

What is the semaglutide compounding ban of 2026?

There is no single law titled the "semaglutide compounding ban." The phrase describes a sequence of FDA actions that together ended the era of widely available compounded semaglutide. The trigger was supply: under U.S. law, compounders may make copies of an FDA-approved drug only when that drug is on the FDA's official shortage list.

Semaglutide spent much of 2022 through early 2025 on that list, which is why compounded versions proliferated through telehealth and weight-loss clinics. On February 21, 2025, the FDA updated its database to mark the shortage of all doses of injectable semaglutide as resolved, removing the legal foundation for copy-style compounding (FDA Drug Shortage Database; McDermott Will & Emery, 2025).

The 2026 chapter is the FDA's move to make that closure permanent at the wholesale level. In a notice published May 1, 2026, the agency proposed to leave semaglutide — along with tirzepatide and liraglutide — off the section 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk active ingredient (FDA, 2026; Federal Register, May 1, 2026). The public comment period runs through June 30, 2026.

For background on the molecule itself, see our semaglutide complete guide and how it compares in our tirzepatide vs. semaglutide breakdown.

What are 503A and 503B compounding, and why do they matter?

U.S. drug compounding splits into two statutory lanes, and the 2026 rules treat them differently.

503A — traditional pharmacy compounding. A state-licensed pharmacy or physician prepares a medication for an identified individual patient under a valid prescription. 503A compounding does not require FDA approval of the finished product.

503B — outsourcing facilities. These FDA-registered facilities compound in bulk, often without patient-specific prescriptions, and supply clinics and hospitals. They face stricter manufacturing standards and may only compound from bulk substances that appear on the FDA's 503B bulks list (or that are on the shortage list).

The distinction is the heart of the 2026 situation. The May 2026 proposal targets the 503B bulks list — it would block large-scale outsourcing-facility production from bulk semaglutide (FDA, 2026). It does not, by itself, eliminate every form of 503A pharmacy compounding. As the FDA noted, the bulks-list decision "does not affect" the separate authority of 503A pharmacies to compound using the active ingredient found in FDA-approved products, subject to existing requirements (FDA, 2026).

Is compounded semaglutide still legal in 2026?

Mostly no — with a narrow exception. The default answer is that routine compounded semaglutide is no longer legal once the shortage ended, because U.S. law prohibits compounding a drug that is "essentially a copy" of a commercially available, FDA-approved product (FD&C Act §503A; FDA, 2026).

The narrow exception is the clinical-difference exception under 503A. A pharmacy may compound a copy-like product if the prescriber determines and documents that the compounded version produces a significant clinical difference for a specific, identified patient — for example, a documented allergy to an excipient in the commercial product, or a dose or concentration not commercially available (Foley & Lardner, 2026; McDermott Will & Emery, 2025). Even then, federal rules generally limit a 503A prescriber to a small number of such "copy" prescriptions per month (commonly cited as up to four monthly for essentially-a-copy products), and the documentation must be patient-specific (Foley & Lardner, 2026). [VERIFY: the precise four-prescriptions-per-month figure and its statutory basis]

What is not legal in 2026: bulk telehealth-driven compounding of standard-dose semaglutide marketed to the general public, and 503B outsourcing-facility production from bulk semaglutide once the proposal is finalized. Legal status varies by jurisdiction and continues to evolve; consult a lawyer for binding advice.

What happened to the semaglutide shortage and the enforcement deadlines?

The timeline below tracks the regulatory facts.

Sources: FDA Drug Shortage Database; McDermott Will & Emery (2025); Federal Register (May 1, 2026); FDA press announcement (2026).

When the FDA declares a shortage resolved, it typically grants a short wind-down period rather than an immediate cutoff, which is why the 503A and 503B discretion dates fell weeks after the February 2025 resolution. Tirzepatide — the other major GLP-1 — followed a parallel but earlier path: the FDA first removed it from the shortage list in October 2024 and reaffirmed that determination by declaratory order on December 19, 2024 (FDA, 2024). For the wider drug class, see our GLP-1 peptides explainer.

What about the July 2026 PCAC meeting — does it cover semaglutide?

This is a common point of confusion. The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026, but its agenda is about research peptides, not GLP-1 weight-loss drugs.

According to the FDA advisory-committee calendar and the April 16, 2026 Federal Register meeting notice, the committee will discuss whether to add several bulk peptide substances to the 503A bulks list, including BPC-157, KPV, TB-500, and MOTS-c on July 23, and emideltide (DSIP), Semax, and Epitalon on July 24 (FDA Advisory Committee Calendar, 2026; Federal Register, April 16, 2026).

Semaglutide is not on the PCAC July 2026 agenda. Its status is governed by the separate 503B bulks-list proposal and the resolved-shortage determination described above. If you arrived here looking for the research-peptide review, that is a distinct regulatory track from the GLP-1 compounding question. Always confirm sourcing legality before acting; our peptide sourcing guide explains how to vet vendors and verify certificates of analysis.

Why does semaglutide work, and why is demand driving compounding?

Understanding the demand behind compounding helps explain why the ban matters so much to patients. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics an endogenous incretin hormone, slowing gastric emptying and acting on appetite-regulating pathways in the brain (Wilding et al., 2021, NEJM).

The clinical signal is strong in FDA-approved formulations. In the STEP 1 randomized trial, once-weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention produced a mean body-weight reduction of 14.9% at 68 weeks, versus 2.4% with placebo, with 86% of participants losing at least 5% of body weight (Wilding et al., 2021, NEJM). In the SELECT cardiovascular outcomes trial of 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo over a mean 39.8 months (Lincoff et al., 2023, NEJM).

These outcomes apply to the FDA-approved products studied in those trials. Compounded versions are not FDA-approved, are not the products tested in STEP 1 or SELECT, and have not undergone the same review for purity, potency, or sterility. Consult your healthcare provider before starting, stopping, or changing any semaglutide protocol.

What are the safety concerns with compounded semaglutide?

Safety is a central reason the FDA tightened the rules. The agency has repeatedly warned that compounded semaglutide products fall outside the approval process that verifies identity, strength, quality, and sterility, and it has received adverse-event reports involving dosing errors with compounded GLP-1 products (FDA, 2026; FDA adverse-event communications, 2024–2025). [VERIFY: specific FDA adverse-event report counts for compounded semaglutide]

Additional documented concerns include the use of salt forms of semaglutide (such as semaglutide sodium or semaglutide acetate) that differ from the active ingredient in approved products, and unapproved additive ingredients such as B12 in some compounded formulations (FDA, 2026; state board of pharmacy alerts, 2025). Reported side effects of semaglutide generally — including in approved products — commonly include nausea, vomiting, diarrhea, and constipation, with rarer concerns around pancreatitis and gallbladder events (Wilding et al., 2021, NEJM).

None of this is a directive to use or avoid any specific product. It illustrates why regulators distinguish FDA-approved from compounded supply. Consult your healthcare provider before starting any peptide or GLP-1 protocol, and consult a lawyer for binding guidance on legal status in your jurisdiction.

Frequently asked questions

Q: Is compounded semaglutide banned in 2026? A: In effect, yes for routine use. Once the FDA declared the semaglutide shortage resolved in February 2025, the legal basis for copy-style compounding fell away, and enforcement-discretion windows closed in April–May 2025. In 2026 the FDA proposed to keep semaglutide off the 503B bulks list, blocking large-scale outsourcing-facility production. A narrow 503A exception remains for documented, patient-specific clinical differences. Legal status varies by jurisdiction; consult a lawyer.

Q: Can my pharmacy still legally compound semaglutide for me? A: Possibly, but only under a narrow exception. A 503A pharmacy may compound a semaglutide product for you if your prescriber documents a significant clinical difference for your specific situation — for example, a needed dose or concentration not commercially available, or a documented excipient allergy. Routine compounding of standard-dose semaglutide as a cheaper copy of Ozempic or Wegovy is no longer permitted. Consult your healthcare provider.

Q: Why was compounded semaglutide legal before 2025? A: U.S. law allows compounders to make copies of an FDA-approved drug while that drug is on the FDA's official shortage list. Semaglutide was on the shortage list from roughly 2022 to early 2025, which is why compounded versions spread through telehealth. When the FDA marked the shortage resolved on February 21, 2025, that legal exception ended.

Q: What is the difference between 503A and 503B for semaglutide? A: 503A is traditional pharmacy compounding for an identified patient with a prescription. 503B refers to FDA-registered outsourcing facilities that compound in bulk for clinics. The 2026 proposal targets the 503B bulks list, blocking bulk outsourcing-facility production. It does not eliminate every 503A pathway, though 503A copy-compounding is still restricted by the "essentially a copy" rule.

Q: Does the July 2026 PCAC meeting affect semaglutide? A: No. The Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to review research peptides — including BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon — for the 503A bulks list. Semaglutide is not on that agenda. Its status is governed separately by the resolved-shortage determination and the 503B bulks-list proposal.

Q: Are FDA-approved semaglutide products still available? A: Yes. Because the shortage is resolved, brand-name products such as Ozempic, Wegovy, and Rybelsus are commercially available. Cost remains a barrier for many patients, since list prices can exceed $1,000 per month before insurance, which is part of why compounded alternatives were popular. Discuss coverage and options with your healthcare provider.

Q: Is the 2026 ban final? A: Not yet fully. The 503B bulks-list exclusion was a proposal published May 1, 2026, with a public comment period through June 30, 2026, after which the FDA must finalize its decision. The resolved-shortage status and the expired enforcement-discretion windows are already in effect. Rules continue to evolve; verify current status before relying on any compounded source.

References

1. U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. FDA News & Events, 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
2. Federal Register. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act. 91 FR, published May 1, 2026. https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
3. U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. FDA Drug Alerts and Statements, 2025. https://www.fda.gov/drugs/drug-alerts-and-statements
4. McDermott Will & Emery. Semaglutide Shortage Resolved. 2025. https://www.mcdermottlaw.com/insights/semaglutide-shortage-resolved/
5. Foley & Lardner LLP. FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products. 2026. https://www.foley.com/insights/publications/2026/04/fda-clarifies-policies-for-pharmacy-compounders-of-glp-1-products/
6. Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting … Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List. Published April 16, 2026. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
7. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar, 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
8. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989–1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 (PMID: 33567185)
9. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221–2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 (PMID: 37952131)

QA checklist

• BLUF lead 40–60 words, answers the core query first
• At-a-glance block present near top
• Question-form H2s throughout
• 7 self-contained FAQ Q&A blocks
• Byline = Peptides.NYC Editorial Team only; no medical-review claim
• Standard disclaimer block verbatim
• Consult-provider line in dosing/safety sections; consult-a-lawyer in regulatory sections
• ≥5 primary/authoritative citations, inline + numbered; no invented PMIDs/DOIs
• Unverifiable specifics hedged and tagged [VERIFY]
• Word count ≥1500
• QUICK_ANSWER line at very end